Active Post-Market Surveillance of Innovative Devices for Valvular Heart Disease
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Beijing Anzhen HospitalBeijing, ChinaContact: Guangyuan Song, MD, PhDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Anzhen Hospital
- Trial code
- NCT07605624
- Record updated
- 26 May 2026
- Original description
This prospective, multicenter, observational cohort study aims to establish a post-market registry framework to evaluate the real-world clinical applicability, long-term safety, and effectiveness of innovative heart valve devices in China.Read full original descriptionShow less
An Active Post-Market Surveillance Study Assessing the Real-World Clinical Applicability, Long-Term Safety, and Effectiveness of Innovative Medical Devices for Valvular Heart Disease
This prospective, multicenter, observational cohort study aims to establish a post-market registry framework to evaluate the real-world clinical applicability, long-term safety, and effectiveness of innovative heart valve devices in China.
Inclusion: Patients with valvular heart disease (VHD) receiving treatment with prosthetic aortic valve replacement systems (transcatheter and surgical valves), transcatheter mitral valve edge-to-edge repair (TEER) systems, or transcatheter tricuspid valve annuloplasty systems; Age ≥ 18 years; Patients who voluntarily participate in the study and sign the informed consent form; Willing and able to comply with follow-up requirements.